Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Abstract Highlights from EHA 2022 : A Spotlight on Lymphoma

    July 26, 2022 | CME, Medscape Oncology, medical education 

    - PMLiVE

    Spotlight on Lymphoma

    Ahead of EHA 2022, Medscape Education Chief Medical Officer, Hansa Bhargava, MD, caught up with Dr Loretta Nastoupil, US, on the most important abstracts to look out for in lymphoma. Here are some of the highlights…

    1. Update on the ECHELON-1 study in frontline Hodgkin lymphoma, where an OS advantage was seen when bleomycin was replaced with brentuximab vedotin in frontline, ABVD, which is potentially practice-changing.
    2. The results of the Ph 3 SHINE study have been eagerly awaited for many years in untreated mantle cell lymphoma, and showed a significant improvement in PFS with ibrutinib + bendamustine + rituximab and rituximab maintenance vs standard chemoimmunotherapy.
    3. Positive Ph 2 efficacy data with the bispecific antibodies, glofitamab for relapsed/refractory (R/R) diffuse large B-cell lymphoma, and mosunetuzumab for R/R follicular lymphoma, building on the Ph 1 data previously reported.
    4. Other CAR T-cell therapies with novel targets and in other indications are emerging, such as for T-cell lymphoma where there is a high unmet need for new therapies. Some manipulations to manufacturing also result in an auto CAR within 2 days. So, while CAR T-cell therapy is not new, there are new implementations of therapy that have been around for several years.
    5. Important to now learn regarding patient selection, sequencing CD19 directed therapy and how to account for the patient experience for which there will also be more PRO data reported.

    You can also watch the full video here

    About Medscape:
    Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide. Medscape is the leading online global destination for physicians and healthcare professionals, providing over 5 million members with the latest medical news, expert opinion, and precision education (CME and CPD) to improve clinical practice and advance health outcomes. Medscape’s unrivalled membership reach and therapeutic expertise deliver education across 30+ specialties in 40+ learning formats, using the latest digital and live technology.

    This content was provided by Medscape Education

    Company Details

    Medscape Logo

    Medscape Education

    Email
    Website

     Latest Content from  Medscape Education 

    Medscape Brings Impact and Data to ESPGHAN

    The ESPGHAN Congress in Milan was full of impact as Medscape Education Global presented 5 scientific posters examining the outcomes of their education. The posters detailed the impact Medscape Education...

    Empowering Nurses Through Education

    Nurse education is powerful and makes an impact.

    Pioneering Paths: Women Leadership in Rare Disease

    Rare diseases are often thought of as affecting one in 100,000 or one in 1,000,000 people, and that is true for some conditions. But there are many rare diseases that...

    TRANSFORMING CME IMPACT: MEDSCAPE’S GAME-CHANGING APPROACH

    It’s time for the CME industry to evolve. During recent years, access to data, modern technologies, and methodologies have allowed for deeper analysis of data and a better understanding of...

    Why Women in Medicine Should Embrace Social Media

    Of course social media has its downside. But online platforms are a powerful tool for women in medicine in terms of forming communities, fighting misinformation, amplifying one another, and galvanizing...

    Exceptional Impact Presented at ECCMID 2024

    The ECCMID conference in Barcelona, Spain marked the start of Medscape’s publication season in Europe. With three posters being presented at the conference, Medscape shared highlights from the powerful impact...

    Showing Deep Expertise at ONS

    The Medscape Oncology team will be connecting with the oncology nursing community this week in Washington, DC for the ONS Congress 2024.  Medscape Oncology has deep expertise in the oncology...

    MEDSCAPE’S NEW AGE OF CERTAINTY FOR CME

    The CME industry is changing. More than ever, activities need to be prioritized and measured to increase their impact on patient outcomes. Improving patient outcomes is the core objective for...

    Getting Past the Old-Fashioned View of Patient Advocacy

    Patient advocacy organizations today are data-driven, doing amazing work — and have the hard evidence to support their impact on patient care. The challenge is getting past the perception of...

    Mile High Impact at AAN 2024

    The Medscape team will be joining our neurology colleagues in Denver, CO for this year’s AAN Annual Meeting. Impact will take center stage at this year’s event as Medscape presents...